Interim President & CEO Jim Janik Returning to Role as Chairman of the Board of Directors MILWAUKEE, March 03, 2025 (GLOBE NEWSWIRE) — Douglas Dynamics, Inc. (NYSE: PLOW), North America’s premier manufacturer and upfitter of work truck attachments and equipment, today announced the Board of Directors has appointed Mark Van Genderen as President and Chief Executive Officer (CEO), effective immediately. He will also join the Board of Directors effective immediately. Mr. Van Genderen has been with the company for five years, and most recently served as Chief Operating Officer and President of Work Truck Attachments. He succeeds Interim President & CEO, James (Jim) L. Janik, who will return to his former role as Chairman of the Board of Directors. “Over the past five years, Mark has developed a deep understanding of...

– CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin –– Phase 1 study in healthy volunteers ongoing – HAMPTON, N.J., March 03, 2025 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive preclinical data from CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis—thymic stromal lymphopoietin (TSLP) and mast cell depletion via stem cell factor (SCF) starvation. The data demonstrate that CDX-622 neutralizes both SCF and TSLP, reducing tissue mast cells and inhibiting Type 2 inflammatory responses, supporting its potential to improve clinical activity over single target inhibition in inflammatory diseases and fibrotic disorders. The data were presented by Diego Alvarado, PhD,...

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. “Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformative medicines. We are honored to welcome him to our Board at a defining moment for Ovid,” said Jeremy Levin, D.Phil, MB BChir, Chairman and CEO of Ovid Therapeutics. “With our advancing pipeline, including our novel KCC2 direct activators and OV329 epilepsy program, Ovid stands on the cusp of delivering real change for neurological and psychiatric...

REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on March 3, 2025, the compensation committee of Biomea’s board of directors granted one new employee non-qualified stock options to purchase an aggregate of 25,000 shares of the Company’s common stock. The shares underlying the employee’s stock options will vest 1/16 on a quarterly basis over four years, subject to the employee’s continued employment with the Company on such vesting dates. The above-described award was made under Biomea’s 2023 Inducement Equity Plan (the “Plan”). The above-described award was granted as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and...

– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales – ANN ARBOR, Mich., March 03, 2025 (GLOBE NEWSWIRE) — Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with CSL Seqirus (ASX:CSL) for the exclusive rights to commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia and New Zealand. Under the terms of the agreement, Esperion will receive an upfront and near-term milestone payments and will be responsible for supplying finished product to CSL Seqirus at a profitable transfer price. In Australia, cardiovascular disease affects 1.2 million people and is a leading cause of death. In New Zealand, an estimated 175,000 adults are living with cardiovascular disease,...

CARLSBAD, Calif., March 03, 2025 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during Leerink’s Global Healthcare Conference on Monday, March 10, 2025, at 1:40 p.m. ET in Miami. A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation. About Design TherapeuticsDesign Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or...

Andrea White Named Chief Human Resources Officer of SonocoAndrea White Sonoco Chief Human Resources OfficerHARTSVILLE, S.C., March 03, 2025 (GLOBE NEWSWIRE) — Sonoco Products Company (NYSE: SON), a global leader in high-value sustainable packaging, announced that Andrea White, has been named Chief Human Resources Officer and has been elected a corporate officer by the Company’s Board of Directors. She is a member of the Company’s Executive Committee and reports to Howard Coker, President and CEO. White, 50, is an 18-year Sonoco veteran beginning her career as a Reliability Engineer after working in Manufacturing and Process Improvement for Milliken & Company for over a decade. She quickly expanded her roles within the Company to serve as a Global Maintenance Excellence Manager before assuming the position of Director,...

GREENWICH, Conn., March 03, 2025 (GLOBE NEWSWIRE) — Gabelli Funds is hosting its 16th Annual Specialty Chemicals Symposium taking place at The Harvard Club in New York, NY on Thursday, March 20, 2025.  The symposium will draw a variety of companies, with a focus on pricing power, margin recovery, interest rates, inventory stabilization, global trade policy, demand trends, and the M&A environment.  Attendees will also have the opportunity to meet with managements in a one-on-one setting. Agenda:8:20am Opening Remarks Rosemarie Morbelli, CFA Gabelli Funds    Wayne Pinsent, CFA Gabelli Funds     8:30 Cabot Corporation (NYSE: CBT)* To Be Confirmed          9:00 Arq, Inc. (NASDAQ: ARQ) Bob Rasmus, President & CEO          9:30 BASF Corporation (XETRA: BAS.DE) Alex Koehler, Investor Relations          10:00 American...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s fourth quarter 2024 financial results on Monday, March 10, 2025, before the open of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus infection,...

GEORGE TOWN, Cayman Islands, March 03, 2025 (GLOBE NEWSWIRE) — Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water supply and treatment plants, has been invited to attend the 37th Annual ROTH Conference being held at The Laguna Cliffs Marriott in Dana Point, California, on March 16-18, 2025.The conference will feature on-demand presentations by companies across a range of industry sectors, in-person one-on-one and small group meetings, industry panels, and fireside chats. Past conferences have attracted more than 5,000 participants, comprised of institutional investors, family offices, high-net-worth investors, and equity analysts. On March 17-18, Consolidated Water CEO, Rick McTaggart, will participate in one-on-one meetings with analysts and investors....